Arbutus Biopharma Balance Sheet Health
Financial Health criteria checks 5/6
Arbutus Biopharma has a total shareholder equity of $106.0M and total debt of $7.0M, which brings its debt-to-equity ratio to 6.6%. Its total assets and total liabilities are $144.4M and $38.4M respectively.
Key information
6.6%
Debt to equity ratio
US$6.95m
Debt
Interest coverage ratio | n/a |
Cash | US$126.00m |
Equity | US$106.02m |
Total liabilities | US$38.38m |
Total assets | US$144.40m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: I9DN's short term assets ($132.0M) exceed its short term liabilities ($22.5M).
Long Term Liabilities: I9DN's short term assets ($132.0M) exceed its long term liabilities ($15.9M).
Debt to Equity History and Analysis
Debt Level: I9DN has more cash than its total debt.
Reducing Debt: I9DN's debt to equity ratio has increased from 0% to 6.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: I9DN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: I9DN has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 1% each year.